金龙胶囊联合放化疗对脑胶质瘤手术患者T淋巴细胞亚群及预后的影响

Effects of Jinlong Capsule Combined with Radiotherapy and Chemotherapy on T Lymphocyte Subsets and Prognosis in Patients with Glioma Surgery

目的:研究金龙胶囊联合放化疗对脑胶质瘤手术患者的影响。方法:选取2020年3月~2021年3月本院收治的106例脑胶质瘤手术患者作为研究对象,采用随机数字表法分为对照组和观察组,每组53例。对照组给予放化疗+常规对症治疗,观察组在对照组基础上给予金龙胶囊。比较两组T淋巴细胞亚群(CD3^(+)、CD4^(+)、CD8^(+)水平和CD4^(+)/CD8^(+)比值)、血清肿瘤标志物[癌胚抗原(CEA)、糖类蛋白153(CA153)、血管内皮生长因子(VEGF)]、临床疗效、不良反应及生存情况。结果:治疗3个月后,两组患者CD3^(+)、CD4^(+)水平和CD4^(+)/CD8^(+)比值均降低,且观察组高于对照组(P<0.05);CD8^(+)水平均升高,且观察组低于对照组;治疗后,两组患者血清CEA、CA153和VEGF水平均降低,且观察组低于对照组(P<0.05);观察组客观缓解率和疾病控制率高于对照组(P<0.05);观察组不良反应总发生率(47.17%)低于对照组(62.27%,P>0.05);观察组1年总生存率(81.13%)高于对照组(56.60%,P<0.05)。结论:金龙胶囊联合放化疗治疗脑胶质瘤手术患者的临床疗效优于单独放化疗,能减轻免疫抑制作用,调节血清肿瘤标志物水平,提高患者生存率,且安全性较好。

Objective:To investigate the effect of Jinlong capsule combined with radiotherapy and chemotherapy on patients with glioma surgery.Methods:A total of 106 patients with brain glioma who were treated in our hospital from March 2020 to March 2021 were selected as research subjects,and randomly divided into control group and observation group,53 cases in each group.The control group was given radiotherapy and chemotherapy+conventional symptomatic treatment,and the observation group was given Jinlong capsule on the basis of the control group.The clinical efficacy,T lymphocyte subsets(CD3^(+),CD4^(+),CD8^(+),CD4^(+)/CD8^(+)ratio),serum tumor markers[carcinoembryonic antigen(CEA),carbohydrate antigen 153(CA153),vascular endothelial growth factor(VEGF)],adverse reactions and survival were compared.Results:After 3 months of treatment,the levels of CD3^(+)and CD4^(+)and the ratio of CD4^(+)/CD8^(+)in the two groups were decreased,and the objective remission rate and disease control rate in the observation group were higher than those in the control group(P<0.05).The CD8^(+)were higher,and CD8^(+)in the observation group was lower than that in the control group.Serum levels of CEA,CA153 and VEGF after treatment were significantly lower than those before treatment,and the observation group were lower than that in the cantrol group(P<0.05).The objective remission rate and disease control rate of observation group were higher than those of control group(P<0.05).The total incidence of adverse reactions in the observation group(47.17%)was lower than that in the control group(62.27%,P>0.05);the 1-year overall survival rate in the observation group(81.13%)was higher than that in the control group(56.60%,P<0.05).Conclusion:The clinical efficacy of Jinlong capsule combined with radiotherapy and chemotherapy in the treatment of glioma patients is better than that of radiotherapy and chemotherapy alone,and it can reduce the immunosuppressive effect,downregulates the level of serum tumor markers,has good safety and can improve the survival rate of patients.